PT  - JOURNAL ARTICLE
AU  - Hanly, Mark
AU  - Churches, Tim
AU  - Fitzgerald, Oisín
AU  - McIntyre, C Raina
AU  - Jorm, Louisa
TI  - Vaccinating Australia: How long will it take?
AID  - 10.1101/2021.02.02.21250979
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.02.21250979
4099  - http://medrxiv.org/content/early/2021/02/04/2021.02.02.21250979.short
4100  - http://medrxiv.org/content/early/2021/02/04/2021.02.02.21250979.full
AB  - The Australian Government’s COVID-19 vaccine rollout strategy is scheduled to commence in late February 2021 and aims to vaccinate the Australian adult population by the end of October 2021. The task of vaccinating some 20 million people within this timeframe presents considerable logistical challenges. Key to meeting this target is the rate of vaccine delivery: the number of vaccine doses that can be administered per day. In the opening phase, high priority groups will receive the Pfizer/BioNTech vaccine through hospital hubs at an initial rate of 80,000 doses per week. However, pending regulatory approval, the currently announced plan appears to be to distribute the AstraZeneca vaccine to the bulk of the popluation through a combination of general practices and community pharmacies. Here, we run a series of projections to estimate how long it will take to vaccinate the Australian population under different assumptions about the rate of vaccine administration as well as the schedule for second doses and prevalence of vaccine hesitancy. Our analysis highlights the ambitious rate of vaccine administration that will be neccessary to meet the Australian Government completion target of October 2021. A rate of 200,000 doses per day would comfortably meet that target; 80,000 doses a day would see roll-out extended until mid-2022. Speed is of the essence when it comes to vaccine rollout: protecting the population quickly will minimise the risk of sporadic and costly lockdowns lockdowns and the potential for small, local clusters getting out of control and sparking new epidemic waves. The government should gather all its resources to maximise the daily vaccination rate, ideally aiming to ramp up administration to at least 200,000 doses per day as quickly as possible. Quickly achieving and maintaining this pace will likely require dedicated large-scale vaccination sites that are capable of delivering thousands of doses a week in addition to the enthusiastic participation of GP practices and community pharmacies around the country. Lessons on the neccessary logistical planning, including coordination of delivery, ultra-cold-chain storage and staffing, can potentially be learned from Israel, where between 7,000 and 20,000 vaccinations per million population have been delivered daily throughout January.Competing Interest StatementMark Hanly receives funding from the National Health and Medical Research Council (NHMRC) and the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE). Timothy Churches receives funding from the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE), Australian Research Data Commons (ARDC), UNSW Sydney and the Ingham Institute for Applied Medical Research. Oisin Fitzgerald receives funding from the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE). C Raina MacIntyre receives funding from Medical Research Futures Fund and NHMRC. She has consulted for Astra Zeneca and Janssen on COVID-19 vaccines and been on an advisory board for Seqirus on COVID-19 vaccines. In the past she has been on advisory boards and had support from vaccine manufacturers Sanofi, Seqirus, Merck, Pfizer, GSK, Bavarian Nordic and Emergent Biosolutions for other vaccines. Louisa Jorm receives funding from the Medical Research Futures Fund, Australian Research Data Commons, NHMRC, UNSW Sydney and the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE).Funding StatementThis research was supported by the generous assistance of Ian Sharp, philanthropic supporter of UNSW research, and by a research seed grant provided by the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) Infectious diseases, Immunity and Inflammation (Triple-I) Clinical Academic Group.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A - only published data was used in this mathematical modelling study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData generated through our projections are hosted in the GitHub repo for this project. Data on the daily vaccinations per million population were accessed through ourworldindata.org https://ourworldindata.org/covid-vaccinations#how-many-covid-19-vaccine-doses-are-administered-daily